RxDoctor Payments Data

Julia Malin, MD

Family Medicine · Ballston Spa, NYNPI 1881759355

Payments from drug & device makers

$10,779in general payments, 2019–2025

Across 445 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • Novo Nordisk$840
  • Pfizer$833
  • Otsuka America Pharmaceutical, Inc.$618
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$10,58598%
  • Education$1942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,779 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$13,622
Medicare patients
54
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$63,088
DescovyEmtricitabine/Tenofov Alafenam11$24,137
JardianceEmpagliflozin28$23,670
EliquisApixaban32$19,575
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,756
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,470
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen101$4,190
Albuterol Sulfate HfaAlbuterol Sulfate94$3,443
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,131
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,091
Oxycodone Hcl59$1,880
Levothyroxine Sodium119$1,618
Omeprazole150$1,571
Aripiprazole23$1,312
Duloxetine Hcl70$1,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$840$63,08863 claims
Boehringer IngelheimJardiance$256$23,67028 claims
PfizerEliquis$833$19,57532 claims
GSKTrelegy Ellipta$1,734$12,75616 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,618119 claims
Almatica Pharma LLCSertraline Hcl$19$45554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Ballston Spa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →